Early postoperative plasma circulating tumour DNA for molecular residue disease detection and recurrence risk evaluation in surgical non-small cell lung cancer

Jie Tang; Yingsong Tian; Song Wang; Yong Liu; Manjun Chen; Xudong Yang; Xinghe Tong; Mengtian Wang; Yunping Zhao; Jiaohui Pang; Qiuxiang Ou; Xiaobo Chen

doi:10.1002/ctm2.70056

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (10) : e70056 DOI: 10.1002/ctm2.70056

LETTER TO THE JOURNAL

Early postoperative plasma circulating tumour DNA for molecular residue disease detection and recurrence risk evaluation in surgical non-small cell lung cancer

Author information +

History +

PDF

Cite this article

Download citation ▾

Jie Tang, Yingsong Tian, Song Wang, Yong Liu, Manjun Chen, Xudong Yang, Xinghe Tong, Mengtian Wang, Yunping Zhao, Jiaohui Pang, Qiuxiang Ou, Xiaobo Chen. Early postoperative plasma circulating tumour DNA for molecular residue disease detection and recurrence risk evaluation in surgical non-small cell lung cancer. Clinical and Translational Medicine, 2024, 14(10): e70056 DOI:10.1002/ctm2.70056

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Chen K, Zhao H, Shi Y, et al. Perioperative dynamic changes in circulating tumor DNA in patients with lung cancer (DYNAMIC). Clin Cancer Res. 2019; 25(23): 7058-7067.

[2]	Zhang JT, Liu SY, Gao W, et al. Longitudinal undetectable molecular residual disease defines potentially cured population in localized non-small cell lung cancer. Cancer Discov. 2022; 12(7): 1690-1701.

[3]	Mumford JL, He XZ, Chapman RS, et al. Lung cancer and indoor air pollution in Xuan Wei. China Science. 1987; 235(4785): 217-220.

[4]	Robichaux JP, Le X, Vijayan RSK, et al. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature. 2021; 597(7878): 732-737.

[5]	Lv L, Liu Z, Liu Y, et al. Distinct EGFR mutation pattern in patients with non-small cell lung cancer in Xuanwei region of China: a systematic review and meta-analysis. Front Oncol. 2020; 10: 519073.

[6]	Wang S, Jia M, He Z, Liu XS. APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer. Oncogene. 2018; 37(29): 3924-3936.

[7]	Chang L, Chang M, Chang HM, Chang F. Microsatellite instability: a predictive biomarker for cancer immunotherapy. Appl Immunohistochem Mol Morphol. 2018; 26(2): e15-e21.

[8]	Chen G, Peng J, Xiao Q, et al. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. J Hematol Oncol. 2021; 14(1): 80.

[9]	Zhong R, Gao R, Fu W, et al. Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis. BMC Med. 2023; 21(1): 180.

[10]	Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017; 545(7655): 446-451.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.